Cargando…

53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells

BACKGROUND: Mutations in DNA damage response factors BRCA1 and BRCA2 confer sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors in breast and ovarian cancers. BRCA1/BRCA2-defective tumors can exhibit resistance to PARP inhibitors via multiple mechanisms, one of which involves loss of 53BP1....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Ruoxi, Ma, Fei, Zhang, Weimin, Yu, Xiying, Li, Qing, Luo, Yang, Zhu, Changjun, Jiang, Wei, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5017014/ https://www.ncbi.nlm.nih.gov/pubmed/27613518 http://dx.doi.org/10.1186/s12885-016-2754-7

Ejemplares similares

Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
por: Hong, Ruoxi, et al.
Publicado: (2016)

ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
por: Gilardini Montani, Maria Saveria, et al.
Publicado: (2013)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

ATM depletion induces proteasomal degradation of FANCD2 and sensitizes neuroblastoma cells to PARP inhibitors
por: Parvin, Sultana, et al.
Publicado: (2023)

Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition
por: Aguilar-Quesada, Rocío, et al.
Publicado: (2007)

The role of ATM and 53BP1 as predictive markers in cervical cancer
por: Roossink, Frank, et al.
Publicado: (2012)

Formation of 53BP1 foci and ATM activation under oxidative stress is facilitated by RNA:DNA hybrids and loss of ATM-53BP1 expression promotes photoreceptor cell survival in mice
por: Bhatia, Vaibhav, et al.
Publicado: (2018)

Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition
por: D’Ambrosio, Concetta, et al.
Publicado: (2022)

RYBP Sensitizes Cancer Cells to PARP Inhibitors by Regulating ATM Activity
por: Maybee, Deanna V., et al.
Publicado: (2022)

BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
por: Nacson, Joseph, et al.
Publicado: (2018)

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
por: Williamson, Chris T, et al.
Publicado: (2012)

ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication
por: Wang, Dejie, et al.
Publicado: (2021)

PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1
por: Belotserkovskaya, Rimma, et al.
Publicado: (2020)

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity
por: Becker, Jordan R., et al.
Publicado: (2018)

TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks
por: Ma, Jian, et al.
Publicado: (2023)

PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
por: Perini, Valentina, et al.
Publicado: (2020)

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
por: Lloyd, Rebecca L., et al.
Publicado: (2020)

ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress
por: Schmidt, Luisa, et al.
Publicado: (2014)

53BP1‐mediated recruitment of RASSF1A to ribosomal DNA breaks promotes local ATM signaling
por: Tsaridou, Stavroula, et al.
Publicado: (2022)

BRCA1 and TP53 codeficiency causes a PARP inhibitor–sensitive erythroproliferative neoplasm
por: Lopez-Perez, Gerardo, et al.
Publicado: (2022)

Genetic polymorphisms and cervical cancer development: ATM G5557A and p53bp1 C1236G
por: OLIVEIRA, S., et al.
Publicado: (2011)

Regulation of pairing between broken DNA-containing chromatin regions by Ku80, DNA-PKcs, ATM, and 53BP1
por: Yamauchi, Motohiro, et al.
Publicado: (2017)

Isorhamnetin Promotes 53BP1 Recruitment through the Enhancement of ATM Phosphorylation and Protects Mice from Radiation Gastrointestinal Syndrome
por: Nishiyama, Yuichi, et al.
Publicado: (2021)

Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells
por: Priya, Bhanu, et al.
Publicado: (2023)

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
por: Li, Junjun, et al.
Publicado: (2022)

ATM Localization and Heterochromatin Repair Depend on Direct Interaction of the 53BP1-BRCT(2) Domain with γH2AX
por: Baldock, Robert A., et al.
Publicado: (2015)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment
por: Ip, Laura R. H., et al.
Publicado: (2015)

Atm heterozygous deficiency enhances development of mammary carcinomas in p53 heterozygous knockout mice
por: Umesako, Seiichi, et al.
Publicado: (2005)

BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer
por: Jacot, William, et al.
Publicado: (2013)

DIPG-19. TARGETING ATM MUTATION IN METASTATIC DIFFUSE MIDLINE GLIOMA – A CASE OF SUSTAINED RESPONSE USING PARP INHIBITOR
por: Tsui, Karen, et al.
Publicado: (2020)

PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
por: Keung, Man Yee T., et al.
Publicado: (2019)

Novel targets for ATM-deficient malignancies
por: Winkler, Johannes, et al.
Publicado: (2014)

PARP inhibitors
por: Anwar, Maheen, et al.
Publicado: (2015)

ATM targets hnRNPK to control p53
por: Blasius, Melanie, et al.
Publicado: (2013)

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
por: Folk, Watson P., et al.
Publicado: (2021)

The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
por: Fenton, Amanda L., et al.
Publicado: (2013)

Reverse the Resistance to PARP Inhibitors
por: Kim, Yevgeniy, et al.
Publicado: (2017)

AHNAK controls 53BP1-mediated p53 response by restraining 53BP1 oligomerization and phase separation
por: Ghodke, Indrajeet, et al.
Publicado: (2021)

Advances and perspectives of PARP inhibitors
por: Yi, Ming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3plojdthhfqbg69l8nkj9msjj5